These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 14746532)

  • 1. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.
    Rastetter W; Molina A; White CA
    Annu Rev Med; 2004; 55():477-503. PubMed ID: 14746532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituxan immunotherapy and zevalin radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
    White CA
    Curr Pharm Biotechnol; 2003 Aug; 4(4):221-38. PubMed ID: 14529425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma.
    Bosly A; Keating MJ; Stasi R; Bradstock K
    Anticancer Drugs; 2002 Nov; 13 Suppl 2():S25-33. PubMed ID: 12710588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab therapy for indolent non-Hodgkin's lymphoma.
    Hagenbeek A; Czuczman MS; Ghielmini M; Herold M; Kimby E; Solal-Céligny P; Unterhalt M
    Anticancer Drugs; 2002 Nov; 13 Suppl 2():S11-7. PubMed ID: 12710586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
    King KM; Younes A
    Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
    Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
    Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is the role of maintenance rituximab in follicular NHL?
    Maloney DG
    Oncology (Williston Park); 2008 Jan; 22(1):20-6; discussion 26, 29, 33-4. PubMed ID: 18251281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab: a B-cell depletion therapy for dermatologic disease.
    Prajapati V; Mydlarski PR
    Skin Therapy Lett; 2007; 12(6):6-9. PubMed ID: 17762903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis.
    Looney RJ
    Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii13-ii17. PubMed ID: 15851522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
    Fanale MA; Younes A
    Drugs; 2007; 67(3):333-50. PubMed ID: 17335294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rituximab].
    Okamoto R; Maeda Y; Sasaki T
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1085-93. PubMed ID: 12938262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Proteins in haematology].
    Clarenbach RE; Mey U
    Ther Umsch; 2011 Nov; 68(11):610-7. PubMed ID: 22045523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab: ongoing and future clinical development.
    Grillo-López AJ; Hedrick E; Rashford M; Benyunes M
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):105-12. PubMed ID: 11842397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR; Bonavida B
    Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
    Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
    Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B; Santos ES
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases.
    Kazkaz H; Isenberg D
    Curr Opin Pharmacol; 2004 Aug; 4(4):398-402. PubMed ID: 15251135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.